These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 19675181)

  • 1. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes.
    Gagliardini E; Corna D; Zoja C; Sangalli F; Carrara F; Rossi M; Conti S; Rottoli D; Longaretti L; Remuzzi A; Remuzzi G; Benigni A
    Am J Physiol Renal Physiol; 2009 Nov; 297(5):F1448-56. PubMed ID: 19675181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
    Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes.
    Zoja C; Cattaneo S; Fiordaliso F; Lionetti V; Zambelli V; Salio M; Corna D; Pagani C; Rottoli D; Bisighini C; Remuzzi G; Benigni A
    Am J Physiol Renal Physiol; 2011 Nov; 301(5):F1114-23. PubMed ID: 21816757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy.
    Gross ML; El-Shakmak A; Szábó A; Koch A; Kuhlmann A; Münter K; Ritz E; Amann K
    Diabetologia; 2003 Jun; 46(6):856-68. PubMed ID: 12802493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis.
    Zoja C; Abbate M; Corna D; Capitanio M; Donadelli R; Bruzzi I; Oldroyd S; Benigni A; Remuzzi G
    Am J Kidney Dis; 1998 Mar; 31(3):453-63. PubMed ID: 9506682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
    Blanco S; Vaquero M; Gómez-Guerrero C; López D; Egido J; Romero R
    Am J Hypertens; 2005 Apr; 18(4 Pt 1):557-65. PubMed ID: 15831368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of {alpha}8-integrin aggravates podocyte injury in experimental diabetic nephropathy.
    Hartner A; Cordasic N; Menendez-Castro C; Volkert G; Yabu JM; Kupraszewicz-Hutzler M; Rascher W; Hilgers KF
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1151-7. PubMed ID: 20826576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
    Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
    Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases.
    McLennan SV; Kelly DJ; Cox AJ; Cao Z; Lyons JG; Yue DK; Gilbert RE
    Diabetologia; 2002 Feb; 45(2):268-75. PubMed ID: 11935159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of combining ACE inhibitor and statin in severe experimental nephropathy.
    Zoja C; Corna D; Rottoli D; Cattaneo D; Zanchi C; Tomasoni S; Abbate M; Remuzzi G
    Kidney Int; 2002 May; 61(5):1635-45. PubMed ID: 11967013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3',5' guanosine monophosphate (cGMP) level in podocytes.
    Fang L; Radovits T; Szabó G; Mózes MM; Rosivall L; Kökény G
    Nephrol Dial Transplant; 2013 Jul; 28(7):1751-61. PubMed ID: 23203993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis.
    Mathew R; Futterweit S; Valderrama E; Tarectecan AA; Bylander JE; Bond JS; Trachtman H
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F911-21. PubMed ID: 15942051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats.
    Sun SZ; Wang Y; Li Q; Tian YJ; Liu MH; Yu YH
    Chin Med J (Engl); 2006 May; 119(10):814-21. PubMed ID: 16732983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes.
    Benigni A; Colosio V; Brena C; Bruzzi I; Bertani T; Remuzzi G
    Diabetes; 1998 Mar; 47(3):450-6. PubMed ID: 9519753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy.
    Remuzzi A; Fassi A; Bertani T; Perico N; Remuzzi G
    Am J Kidney Dis; 1999 Oct; 34(4):626-32. PubMed ID: 10516341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining lisinopril and l-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis.
    Zoja C; Benigni A; Camozzi D; Corna D; Longaretti L; Todeschini M; Remuzzi G
    Kidney Int; 2003 Sep; 64(3):857-63. PubMed ID: 12911535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade.
    Mifsud SA; Allen TJ; Bertram JF; Hulthen UL; Kelly DJ; Cooper ME; Wilkinson-Berka JL; Gilbert RE
    Diabetologia; 2001 Jul; 44(7):878-82. PubMed ID: 11508273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy.
    Thallas-Bonke V; Coughlan MT; Bach LA; Cooper ME; Forbes JM
    Am J Nephrol; 2010; 32(1):73-82. PubMed ID: 20551625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats.
    Remuzzi A; Malanchini B; Battaglia C; Bertani T; Remuzzi G
    Exp Nephrol; 1996; 4(1):19-25. PubMed ID: 8788596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker.
    Gross ML; Ritz E; Schoof A; Helmke B; Parkman A; Tulp O; Münter K; Amann K
    Lab Invest; 2003 Sep; 83(9):1267-77. PubMed ID: 13679434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.